Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Covidien PLC Announces Definitive Agreement to Acquire CV Ingenuity


Wednesday, 26 Dec 2012 07:00am EST 

Covidien PLC announced a definitive agreement to acquire CV Ingenuity.The companies expect to complete the acquisition in the first calendar quarter of 2013. Financial terms of the transaction were not disclosed. CV Ingenuity, a privately-held company based in Fremont, CA, is focused on improving patient outcomes in the treatment of peripheral arterial disease (PAD) by providing solutions to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. Once the transaction has been completed, Covidien will report the CV Ingenuity business as part of its Vascular product line in the Medical Devices segment. 

Company Quote

90.91
0.06 +0.07%
9 Jul 2014